Cellular Health Market Leader Tru Niagen® Launches Online in Australia
23 mars 2020 06h30 HE
|
ChromaDex Corporation
ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia LOS ANGELES, March 23, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce...
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
12 mars 2020 16h44 HE
|
ChromaDex Corporation
LOS ANGELES, March 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client,...
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
10 mars 2020 16h01 HE
|
ChromaDex Corporation
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru...
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
27 févr. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Feb. 27, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
25 févr. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Feb. 25, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results...
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
12 févr. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement...
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
03 févr. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD)...
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
15 janv. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Jan. 15, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to...
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
06 janv. 2020 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science,...
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
16 déc. 2019 06h30 HE
|
ChromaDex Corporation
LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded...